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Background: Based on the 24-week, prospective, non-interventional, observational study, A1chieve®, we investigated
how health-related quality of life (HRQoL) changed, and the predictors of such changes, in Chinese people with type 2
diabetes mellitus (T2DM) after starting with, or switching to, biphasic insulin aspart 30 (BIAsp 30).
Methods: In total, 8,578 people with T2DM starting treatment with, or switching to, BIAsp 30 were recruited from 130
urban hospitals in China. HRQoL was assessed at baseline and 24 weeks using the EuroQol-5 dimensions (EQ-5D)
questionnaire. Descriptive statistics, paired t-test, and chi-square test were conducted and the linear ordinary least
squares regression model was used to determine predictors for changes in EQ-5D score.
Results: Haemoglobin A1c (HbA1c) decreased from 9.5% to 7.0% after 24 weeks. The reported HRQoL measured by the
EQ-5D visual analogue scale score increased by 6.2 (p < 0.001) from 75.8 to 82.0, and EQ-5D index score increased by
0.018 (p < 0.001) from 0.875 to 0.893 for the cohort over 24 weeks. The percentage of patients reporting no problems
in the mobility, pain/discomfort, and anxiety/depression dimensions of EQ-5D increased significantly (p < 0.001) from
88.4% to 91.4%, 77.3% to 82.8%, and 74.2% to 77.1%, respectively. Patients with higher HbA1c levels at baseline, major
hypoglycaemia or micro-complications exhibited significantly larger changes in EQ-5D scores than those with lower
baseline HbA1c levels, without major hypoglycaemia or micro-complications after controlling for demographics and
other baseline characteristics.
Conclusions: BIAsp 30 treatment was associated with improved glycaemic control and HRQoL in T2DM patients in
China. Patients with worse health conditions were more likely to experience larger improvements in HRQoL than
those with better health conditions.
Trial registration: ClinicalTrials.gov, NCT00869908.
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Globally, the number of people with diabetes has in-
creased at an alarming level, and diabetes is placing a
heavy economic burden on families and healthcare sys-
tems. The number of people with diabetes was estimated
at more than 371 million in 2012, and is expected to be
551.9 million in 2030 [1]. China has become the country
with the largest number of people with diabetes in the
world. The most recent study estimated that the preva-
lence of diabetes among a representative sample of Chinese
adults was 11.6% and the prevalence of pre-diabetes was
50.1%, which corresponded to 113.9 million and 493.4
million people, respectively, in 2010 [2]. The Chinese
Diabetes Society of the Chinese Medical Association and
International Diabetes Federation estimated that 13% of
total medical expenditures in China were directly caused
by diabetes in 2010 [3].
Diabetes is a debilitating disease characterized by defi-
ciencies in insulin secretion, insulin action, or both, lead-
ing to chronic hyperglycaemia [4]. Insulin treatment is the
inevitable choice for people with type 2 diabetes (T2DM)
as diabetes progresses. It is typically used after glycaemic
control fails or is not maintained with lifestyle changes
and combinations of oral anti-diabetic medications [5].
Insulin treatment can improve glycaemic control, prevent
the development of long-term complications of diabetes
[6], and influence patients’ quality of life [7].
There are a few studies concerning the impacts of
insulin use on patients’ health-related quality of life
(HRQoL), with the impacts recorded ranging from
positive [8-10] to negative [11-13]. There are no studies
regarding whether insulin therapy improves or decreases
patients’ quality of life in a Chinese setting. The purpose
of this study was to assess how HRQoL changed, and
the predictors of such changes, after starting with, or
switching to, biphasic insulin aspart 30 (BIAsp 30, 30%
soluble insulin aspart, 70% protamine-crystallized insulin
aspart) over a 24-week period among people with T2DM




A1chieve® was a 24-week, international, prospective,
multicentre, non-interventional, observational study of
people with T2DM in non-Western countries who had
begun using basal insulin detemir, bolus insulin aspart
and premixed insulin BIAsp 30, alone or in combination
[14]. It was the largest observational study ever conducted
in insulin therapy and was carried out in 28 countries
across four continents (Asia, Africa, South America and
Europe). Individuals with type 2 diabetes with no prior
history of using the study insulins previously, and who
had been started on one of the insulins in the 4 weeksprior to the study start are eligible for this study. People
with hypersensitivity to the study insulins or excipients,
and women who were pregnant, breast feeding, or who
intended to become pregnant within 6 months of the
study are excluded. The therapies were prescribed by the
physicians in the course of normal clinical practice and
treatment demand rather than randomly assigned by the
researchers. The study was conducted in accordance with
the Declaration of Helsinki. The ethics committee ap-
proval was obtained for each country, and all participants
gave written, informed consent prior to their inclusion in
the study. In China, central ethics committee approval
was performed in China-Japan Friendship Hospital. The
coordinating sites accept the central ethics committee
approval or further conduct the ethics committee approval
by ethics committee of their own hospitals (Additional
file 1).
The Chinese cohort that either started (6,612) or were
switched (1,966) to BIAsp 30 in the A1chieve® study
consisted of 8,578 people with T2DM from 130 urban
hospitals in China. They were recruited between January
2009 and June 2010, and had an average observation
period of six months. Approval from ethics committees
were obtained at all the study sites.
Clinical endpoints
Clinical endpoints including safety and effectiveness
outcomes were evaluated. Safety assessment included the
incidence of serious adverse drug reactions (SADRs),
including major hypoglycaemic events, the change in
number of hypoglycaemic, the change in number of
nocturnal hypoglycaemic event, and the number of
adverse drug reactions (ADRs) from baseline to final visit.
Effectiveness assessments included change in Haemoglobin
A1c (HbA1c), fasting plasma glucose (FPG), postprandial
plasma glucose (PPG), body weight between baseline and
interim and final visits, and change in systolic blood pres-
sure (SBP) and lipid profile at the final visit.
HRQoL measurement
The HRQoL was measured by the Chinese version of EQ-
5D questionnaire at baseline and after 24 weeks of therapy.
The EQ-5D consists of a descriptive system of five dimen-
sions: mobility, self-care, usual activities, pain/discomfort,
and anxiety/depression. Each of the five dimensions can
take one of three responses recording different level of
severity: no problems, some or moderate problems and
extreme problems. These responses could be converted
into a single utility value using the EQ-5D preference
weights elicited from general population samples. The EQ-
5D also includes a visual analogue scale (VAS) recording
the respondents’ direct valuation of their current HRQoL
state on a graduated (0− 100) scale with higher scores for
higher HRQoL [15]. The Chinese version of the EQ-5D
Table 1 Characteristics of A1chieve® study respondents in insulin-naïve and insulin-experienced groups, and in the
total cohort
Insulin experienced N = 1966 Insulin naïve N = 6612 Total cohort N = 8578
Gender Male, % 1104 (56.2) 3786 (57.3) 4890 (57.0)
Age Years, mean (sd) 56.7 (15.2) 54.3 (14.2) 54.9 (14.4)
Weight Kg, mean (sd) 68.2 (11.2) 68.1 (11.6) 68.1 (11.5)
BMI Kg/m2, mean (sd) 24.8 (3.3) 24.6 (3.3) 24.7 (3.3)
Duration of diabetes Years, mean (sd) 9.3 (6.8) 5.0 (5.4) 6.0 (6.0)
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and reliability have been assessed in mainland China
[17-19] and it has been used for studies of different popula-
tions in mainland China [20-22].
Statistical analyses
Descriptive analysis and multivariable regression were
performed using SAS (Version 9.1.3, SAS Institute Inc.,
NC 27513-2414, USA). The change from baseline to
24 weeks in clinical endpoints, HRQoL with the EQ-5D
VAS, and health utility value as continuous variables,
were analysed with the Wilcoxon signed-rank test. The
UK preference weights were used for calculation of EQ-Table 2 HbA1c, body weight and hypoglycaemia in insulin-na
cohort
Insulin-experi
HbA1c (%) N 1056
Baseline 9.1 (2.3)
Week 24 7.0 (1.1)
Change -2.0 (2.2)
P value <0.001
Body weight (kg) N 1459
Baseline 68.7 (11.2)
Week 24 69.2 (10.9)
Change 0.5 (3.0)
P value <0.001
Overall hypoglycaemia (events/patient year) N 1966
Baseline 6.12
Week 24 2.14
Nocturnal hypoglycaemia (events/patient year) N 1966
Baseline 1.65
Week 24 0.42
Major hypoglycaemia (events/patient year) N 1966
Baseline 0.37
Week 24 0.00
Minor hypoglycaemia (events/patient year) N 1966
Baseline 5.75
Week 24 2.14
Data are mean (sd), n or incidence.5D utility value because Chinese preference weights were
still to be established.
The change in the percentage of people reporting no
problem in EQ-5D descriptive dimensions was analysed
with a chi-square test. For descriptive analysis, the total co-
hort was divided into subgroups of insulin-naïve people
(those not taking insulin therapy at baseline) and previously
insulin-experienced people (current insulin users). Linear
OLS regression was further employed to explore predictors
of the changes in EQ-5D score. Independent variables
included patients’ demographics (age and sex), health
conditions (macro-complications, micro-complications,
duration of diabetes, body mass index (BMI), HbA1c, SBP,ïve and insulin-experienced patients, and in the total
enced, N = 1,966 Insulin-naïve, N = 6,612 Total cohort, N = 8,578
3386 4442
9.6 (2.2) 9.5 (2.3)
7.0 (1.0) 7.0 (1.0)
-2.7 (2.2) -2.5 (2.2)
<0.001 <0.001
4600 6059
68.5 (11.3) 68.5 (11.3)
68.8 (10.8) 68.9 (10.8)
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density lipoprotein (LDL)), and other related indicators
(previous insulin experience, total hypoglycaemia and major
hypoglycaemia) at baseline.Results
Demographics and characteristics of respondents
Among the 8,578 people with T2DM, 1,966 (22.9%) were
in the insulin-experienced group and 6,612 (77.1%) in the
insulin-naïve group. The average age was 54.9 (±14.4)
years, and BMI was 24.7 (±3.3) kg/m2 for the total cohort.
The average duration of diabetes was 6.0 (±6.0) years, with
9.3 (±6.8) for the insulin-experienced group and 5.0 (±5.4)
for the insulin-naïve group (Table 1).Table 3 Quality of life in insulin-naïve and insulin-experience
Insulin-exper
EQ-5D VAS (Scale 0-100) N 1390
Baseline 75.3 (14.1)
Week 24 82.0 (11.3)
Change 6.7 (15.8)
P value <0.001
QoL UK (Scale 0-1) N 1406
Baseline 0.851 (0.190)
Week 24 0.886 (0.170)
Change 0.035 (0.228)
P value <0.001
Mobility dimension N 1416
No problems with walking (%) Baseline 1197 (84.5)
Week 24 1289 (91.0)
P value <0.0001
Self-care dimension N 1415
No problems with self-care (%) Baseline 1301 (91.9)
Week 24 1280 (90.5)
P value 0.1635
Usual activities dimension N 1415
No problems with performing usual activities (%) Baseline 1222 (86.4)
Week 24 1236 (87.3)
P value 0.4361
Pain/discomfort dimension N 1411
No pain or discomfort (%) Baseline 1007 (71.4)
Week 24 1138 (80.7)
P value <0.0001
Anxiety/depression dimension N 1413
Not anxious or depressed (%) Baseline 1014 (71.8)
Week 24 1067 (75.5)
P value 0.0236
Data are mean (sd), n or percentage.Clinical endpoints
Blood glucose control measures improved markedly in
both insulin-naïve and prior insulin users after 24 weeks
of therapy with BIAsp 30. HbA1c decreased from 9.5%
to 7.0% for the total cohort, with a decrease from 9.1%
to 7.0% for prior insulin users and a decrease from
9.6% to 7.0% for the insulin-naïve group. From a similar
baseline measure, body weight of the two groups
increased slightly by 0.3 kg during the therapy. No
major hypoglycaemia was observed during the study,
and reported hypoglycaemia rates (including overall,
nocturnal and minor hypoglycaemia) decreased in the
total cohort and in both subgroups. All of these results
indicated BIAsp 30 could improve blood glucose con-
trol without increasing the risk of hypoglycaemiad patients, and in the total cohort
ienced, N = 1,966 Insulin-naïve, N = 6,612 Total cohort, N = 8,578
4713 6103
75.9 (13.4) 75.8 (13.6)
82.0 (10.3) 82.0 (10.6)
6.1 (14.4) 6.2 (14.7)
<0.001 <0.001
4814 6220
0.882 (0.176) 0.875 (0.179)
0.896 (0.157) 0.893 (0.160)
0.014 (0.218) 0.018 (0.221)
<0.001 <0.001
4843 6259
4333 (89.5) 5530 (88.4)
4433 (91.5) 5722 (91.4)
0.0005 <0.0001
4845 6260
4475 (92.4) 5776 (92.3)
4483 (92.5) 5763 (92.1)
0.7584 0.6655
4841 6256
4316 (89.2) 5538 (88.5)
4272 (88.2) 5508 (88.0)
0.1578 0.4043
4832 6243
3820 (79.1) 4827 (77.3)
4031 (83.4) 5169 (82.8)
<0.0001 <0.0001
4837 6250
3624 (74.9) 4638 (74.2)
3749 (77.5) 4816 (77.1)
0.0028 0.0002




Macro-complications (yes = 1, no = 0) -0.6064 0.3188
Micro-complications (yes = 1, no = 0) 1.4226 0.0067
Duration of diabetes 0.02993 0.5239
Age 0.02403 0.2699
Male -0.839 0.0944
BMI at baseline -0.1454 0.0554
Pre_study treatment (Insulin naïve = 1,
insulin users = 0)
-0.5474 0.3547
HbA1c at baseline 0.3459 0.0013
SBP at baseline 0.0208 0.1661
Total cholesterol at baseline 0.4528 0.0817
HDL at baseline -2.3537 <.001
LDL at baseline -0.7543 0.0138
Total hypoglycaemia at baseline (yes = 1, no = 0) 0.01457 0.9628
Major hypoglycaemia at baseline (yes = 1, no = 0) 6.957 <.001
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HDL changed favourably, and no SADR was reported
during the study period [23].
Quality of life
Quality of life in the total cohort
As measured by VAS from the EQ-5D (on a scale of
0–100), reported QoL of the total cohort increased by
6.2 from 75.8 at baseline to 82.0 at 24 weeks (p < 0.001).
The health utility value (on a scale of 0–1) increased by
0.018 from 0.875 at baseline to 0.893 at 24 weeks
(p < 0.001).
The increased percentages of people reporting no problem
on the descriptive EQ-5D dimensions indicated that there
were improvements of HRQoL after BIAsp 30 treatment.
The percentages of patients reporting no problems in three
of the five dimensions of EQ-5D—mobility, pain/discomfort
and anxiety/depression—increased significantly from 88.4%
to 91.4% (p < 0.0001), 77.3% to 82.8% (p < 0.0001) and 74.2%
to 77.1% (p = 0.002) after 24 weeks, respectively. There was
no statistical significance found in the percentage of patients
who reported no problems in self-care or who reported no
problems in usual activities (Table 3).
Quality of life for prior insulin-experienced and insulin-naïve
subgroups
Quality of life improved in both insulin-experienced and
insulin-naïve patients. Baseline EQ-5D VAS scores were
similar for both prior insulin-experienced and insulin-
naïve subgroups (75.3, 75.9). There was a significant
increase in both subgroups after 24 weeks (+15.8, +14.4,
p < 0.001). The baseline health utility value of the
insulin-experienced group (0.851) was lower than that of
the insulin-naïve group (0.882). After 24 weeks, the
health utility value of the insulin-experienced and
insulin-naïve groups increased by 0.035 (p < 0.001) and
0.014 (p < 0.001) resulting in a similar health utility value
between the two groups.
The percentages of patients reporting no problems in
dimensions of mobility, pain/discomfort and anxiety/
depression increased significantly from 84.5% to 91.0%
(p < 0.0001), 71.4% to 80.7%(p < 0.0001) and 71.8% to
75.5% (0.0236), respectively, for the prior insulin-
experienced group, and from 89.5% to 91.5% (p = 0.0005),
79.1% to 83.4%(p < 0.0001) and 74.9% to 77.5% (p = 0.0028),
respectively, for the insulin-naïve group. Decrease in per-
centages of patients reporting no problems were seen in
the self-care dimension for the prior insulin-experienced
group (from 91.9% to 90.5%) and in the usual activities
dimension (from 89.2% to 88.2%) for the prior insulin-naïve
group, but neither change was statistically significant. There
were similar percentages of patients reporting no problems
across all other dimensions between the two groups
(Table 3).Linear OLS regression for the change in EQ-5D score
Patients with higher HbA1c levels at baseline, having major
hypoglycaemia or micro-complications exhibited signifi-
cantly larger changes in EQ-5D scores than those with
lower baseline HbA1c levels, without major hypoglycaemia
or micro-complications after controlling for demographics
and other baseline characteristics. HDL and LDL at base-
line were negatively associated with change in EQ-5D
scores. Other variables such as age, sex, duration of
diabetes, and patients’ prior insulin experience were not
significantly associated with change in HRQoL (Table 4).
Discussion
This was the first study examining the impact of BIAsp 30
on HRQoL of people with T2DM in China. The result
showed that people with T2DM starting with, or switching
to, BIAsp 30 experienced significantly increased HRQoL
over 24 weeks. The findings of this study were consistent
with previous studies [24,25] in other countries based on
A1chieve® that evaluated how patients’ HRQoL changed
after BIAsp 30 treatment.
The efficacy and safety of BIAsp 30 compared with
other insulins were shown in randomized controlled trials
[26-30], and the effectiveness of BIAsp 30 in near-routine
clinical practice was demonstrated by observational studies
[31,32]. This study extended the results from clinical
outcomes of BIAsp 30 and added additional evidence for
decision making by assessment of humanistic outcomes.
HRQoL was considered as a multidimensional concept
reflecting patients’ subjective perceptions of their physical,
mental and social functioning [33]. Measuring HRQoL
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clinical practice, and allowed a comprehensive evaluation
of the health intervention. There was evidence that proper
assessment of HRQoL during healthcare management can
result in improvements to the patients’ health [34].
BIAsp30 treatment could be the most likely factor for
improvements in HRQoL in this study. After treatment
of BIAsp30, the patients’ glycaemic control improved
and rates of hypoglycaemic events decreased, and it is
recognized both of these could lead to improvement in
HRQoL [35,36]. However, since the A1chieve® was non-
randomised and lacked a standardised treatment proto-
col, it should be noted that factors other than BIAsp 30
therapy itself could contribute to the improvements as
well. The circumstances in which BIAsp 30 was started
were unknown, and patients’ self-management activities
might be enhanced. Concomitant medication and dietary
intake were not controlled either [14].
In addition to the impact of BIAsp 30 therapy on
HRQoL, this paper also examined predictors for such im-
pacts. The results of multivariable linear regression showed
patients with a higher HbA1c level, major hypoglycaemia
or micro-complications at baseline experienced a larger
amount of change in their EQ-5D scores. This finding indi-
cates that patients with worse health conditions at baseline
were more likely to experience larger improvements of
HRQoL than those with better health conditions.
There were several limitations in this study. First,
because evaluation of HRQoL was based on the observa-
tional A1chieve® study, which was non-randomised and
lacked a standardised treatment protocol, confounding fac-
tors such as improvement of life style might affect patients’
HRQol. Second, the UK preference weights used for utility
calculations of EQ-5D in this study might differ from those
of comparable Chinese weights and result in an inaccurate
evaluation of change in HRQoL in Chinese people with
T2DM. Moreover, although EQ-5D has been widely used
in treatment evaluation for diabetes, disease-specific ques-
tionnaires are often regarded as more sensitive than gen-
eric measures such as EQ-5D for capturing the impact of
treatment [6]. All of these issues leave room for future
research.
Conclusion
This study suggested that BIAsp 30 treatment was
associated with improved glycaemic control and HRQoL in
people withT2DM in China. Patients with worse health con-
ditions were more likely to experience larger improvements
of HRQoL than those with better health conditions.
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